logo-loader

Pain Therapeutics shares in a world of pain after FDA panel rejects Remoxy ER

Last updated: 00:25 28 Jun 2018 AEST, First published: 00:12 28 Jun 2018 AEST

A woman clutching her head in pain
The pharmaceutical company has lost nearly three-fourths of its value

Shares of Pain Therapeutics Inc. (NASDAQ:PTIE) fell to a record low Wednesday after a US Food and Drug Administration advisory committee voted against the approval of Remoxy ER for the treatment of severe pain. 

The pharmaceutical company has lost nearly three-fourths of their value, plunging to US$2.15 in morning trade.

Late Tuesday, the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA voted 14 to 3 against Remoxy ER, oxycodone extended-release capsules, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. 

While panel votes are not binding, the FDA usually follows committee recommendations. The FDA is expected to make a decision on Remoxy ER by August 7.

The overprescribing of addictive opioid painkillers to manage pain among patients has triggered a nationwide opioid addiction crisis in America. The vote comes against this backdrop as drug companies race to get new non-addictive painkillers to the market.

The Austin, Texas-based company licensed Remoxy ER from Durect back in 2002.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 26 minutes ago